Among the litany of modest changes that the Trump administration rolled out in its plan to lower drug prices is one big idea that’s already worrying drug makers: a push to consolidate the two disparate Medicare programs that pay for prescription drugs.

Health and Human Services Secretary Alex Azar has been touting the idea all week as a way to bring the negotiating power of the Part D program, which covers seniors’ prescription drugs, into the Part B program, which covers other treatments. “Let me be really clear about this: We are going to bring negotiation to Part B drugs, and we are going to give Part D plans more bargaining power. It’s going to happen,” he said.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • There is no reason not to and multiple reasons we should IF there are negotiations going on with Big Pharma to reduce drug prices for our Healthcare. The fact that we, Americans, should pay more than others countries is PRICE GAUGING. That should be against the law..if it’s not already.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy